|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Chronic Lymphocytic Leukemia (CLL) Prognostic Panel without Karyotype
Test Code17312
CPT Codes
81263, 82232, 88184, 88185 (x2), 88271 (x6), 88275 (x3)
Includes
Beta-2 Microglobulin, Serum
Chronic Lymphocytic Leukemia, IgVH Mutation Status
CD38+/CD19+
FISH, B-Cell Chronic Lymphocytic Leukemia Panel
ZAP-70
Chronic Lymphocytic Leukemia, IgVH Mutation Status
CD38+/CD19+
FISH, B-Cell Chronic Lymphocytic Leukemia Panel
ZAP-70
Preferred Specimen
5 mL whole blood collected in an EDTA (lavender-top) tube and
16 mL whole blood collected in a sodium heparin (green-top) tube and
1 mL serum
16 mL whole blood collected in a sodium heparin (green-top) tube and
1 mL serum
Minimum Volume
3 mL EDTA whole blood • 10 mL sodium heparin whole blood • 0.5 mL serum
Instructions
See individual tests
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 72 hours
Refrigerated: Unacceptable
Frozen: Unacceptable
Refrigerated: Unacceptable
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Hemolysis • Lipemia
Methodology
Flow Cytometry (FC) • Fluorescence in situ Hybridization (FISH) • Immunoturbidometric • Next Generation Sequencing (NGS) • Sequencing
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon, Thurs; Report available: 10 days
Reference Range
See Laboratory Report
Clinical Significance
Chronic Lymphocytic leukemia is the most common leukemia in the Western world. The disease is chronic and most patients may not require therapy in the early stage of the disease. However, in some patients the disease can be aggressive and within a year the tumor mass may increase significantly imposing serious health problems to the patient. It is difficult to determine based on clinical presentation which patient will progress faster than the others. Therefore, there is a need to use more accurate prognostic indicator to predict the clinical course of this disease. The recent advances in CLL therapy and biology made it possible to develop new tests and a combination of these tests (panel) provide more accurate information.
Performing Laboratory
Quest Diagnostics Nichols Institute |
14225 Newbrook Drive |
Chantilly, VA 20153 |